07:00 , Sep 15, 2016 |  BC Innovations  |  Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
07:00 , Aug 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Galectin-4 (LGALS4)

Cancer INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest inhibiting LGALS4 could help treat prostate cancer. In patient tumor samples, high levels of LGALS4 expression were associated with high rates of cancer...
08:00 , Mar 4, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection ABO blood group (ABO) In vitro and mouse studies suggest that the lectins galectin-4 (LGALS4; GAL-4) and LGALS8 (GAL-8) could help kill...